Your browser doesn't support javascript.
loading
Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group.
Amgad, Mohamed; Stovgaard, Elisabeth Specht; Balslev, Eva; Thagaard, Jeppe; Chen, Weijie; Dudgeon, Sarah; Sharma, Ashish; Kerner, Jennifer K; Denkert, Carsten; Yuan, Yinyin; AbdulJabbar, Khalid; Wienert, Stephan; Savas, Peter; Voorwerk, Leonie; Beck, Andrew H; Madabhushi, Anant; Hartman, Johan; Sebastian, Manu M; Horlings, Hugo M; Hudecek, Jan; Ciompi, Francesco; Moore, David A; Singh, Rajendra; Roblin, Elvire; Balancin, Marcelo Luiz; Mathieu, Marie-Christine; Lennerz, Jochen K; Kirtani, Pawan; Chen, I-Chun; Braybrooke, Jeremy P; Pruneri, Giancarlo; Demaria, Sandra; Adams, Sylvia; Schnitt, Stuart J; Lakhani, Sunil R; Rojo, Federico; Comerma, Laura; Badve, Sunil S; Khojasteh, Mehrnoush; Symmans, W Fraser; Sotiriou, Christos; Gonzalez-Ericsson, Paula; Pogue-Geile, Katherine L; Kim, Rim S; Rimm, David L; Viale, Giuseppe; Hewitt, Stephen M; Bartlett, John M S; Penault-Llorca, Frédérique; Goel, Shom.
Affiliation
  • Amgad M; 1Department of Biomedical Informatics, Emory University School of Medicine, Atlanta, GA USA.
  • Stovgaard ES; 2Department of Pathology, Herlev and Gentofte Hospital, University of Copenhagen, Herlev, Denmark.
  • Balslev E; 2Department of Pathology, Herlev and Gentofte Hospital, University of Copenhagen, Herlev, Denmark.
  • Thagaard J; 3DTU Compute, Department of Applied Mathematics, Technical University of Denmark, Lyngby, Denmark.
  • Chen W; Visiopharm A/S, Hørsholm, Denmark.
  • Dudgeon S; FDA/CDRH/OSEL/Division of Imaging, Diagnostics, and Software Reliability, Silver Spring, MD USA.
  • Sharma A; FDA/CDRH/OSEL/Division of Imaging, Diagnostics, and Software Reliability, Silver Spring, MD USA.
  • Kerner JK; 1Department of Biomedical Informatics, Emory University School of Medicine, Atlanta, GA USA.
  • Denkert C; 6PathAI, Cambridge, MA USA.
  • Yuan Y; 7Institut für Pathologie, Universitätsklinikum Gießen und Marburg GmbH, Standort Marburg, Philipps-Universität Marburg, Marburg, Germany.
  • AbdulJabbar K; 8Institute of Pathology, Philipps-University Marburg, Marburg, Germany.
  • Wienert S; German Cancer Consortium (DKTK), Partner Site Charité, Berlin, Germany.
  • Savas P; 10Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK.
  • Voorwerk L; 11Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
  • Beck AH; 10Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK.
  • Madabhushi A; 11Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
  • Hartman J; 7Institut für Pathologie, Universitätsklinikum Gießen und Marburg GmbH, Standort Marburg, Philipps-Universität Marburg, Marburg, Germany.
  • Sebastian MM; 12Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, University of Melbourne, Victoria, Australia.
  • Horlings HM; 13Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.
  • Hudecek J; 14Department of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Ciompi F; 6PathAI, Cambridge, MA USA.
  • Moore DA; 15Case Western Reserve University, Department of Biomedical Engineering, Cleveland, OH USA.
  • Singh R; 16Louis Stokes Cleveland Veterans Administration Medical Center, Cleveland, OH USA.
  • Roblin E; 17Department of Oncology and Pathology, Karolinska Institutet and University Hospital, Solna, Sweden.
  • Balancin ML; 18Departments of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX USA.
  • Mathieu MC; 19Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Lennerz JK; 20Department of Research IT, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Kirtani P; 21Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Chen IC; 22Department of Pathology, UCL Cancer Institute, London, UK.
  • Braybrooke JP; 23Department of Pathology and Laboratory Medicine, Icahn School of Medicine at Mount Sinai, New York, NY USA.
  • Pruneri G; 24Université Paris-Saclay, Univ. Paris-Sud, Villejuif, France.
  • Demaria S; 25Department of Pathology, Faculty of Medicine, University of São Paulo, São Paulo, Brazil.
  • Adams S; 26Department of Medical Biology and Pathology, Gustave Roussy Cancer Campus, Villejuif, France.
  • Schnitt SJ; 27Department of Pathology, Massachusetts General Hospital, Boston, MA USA.
  • Lakhani SR; Department of Histopathology, Manipal Hospitals Dwarka, New Delhi, India.
  • Rojo F; 29Department of Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.
  • Comerma L; 30Nuffield Department of Population Health, University of Oxford, Oxford, UK.
  • Badve SS; 31Department of Medical Oncology, University Hospitals Bristol NHS Foundation Trust, Bristol, UK.
  • Khojasteh M; 32Pathology Department, Fondazione IRCCS Istituto Nazionale Tumori and University of Milan, School of Medicine, Milan, Italy.
  • Symmans WF; 33Weill Cornell Medical College, New York, NY USA.
  • Sotiriou C; 34Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY USA.
  • Gonzalez-Ericsson P; 35Department of Pathology, Brigham and Women's Hospital, Boston, MA USA.
  • Pogue-Geile KL; 36The University of Queensland Centre for Clinical Research and Pathology Queensland, Brisbane, Australia.
  • Kim RS; 37Pathology Department, CIBERONC-Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain.
  • Rimm DL; 38GEICAM-Spanish Breast Cancer Research Group, Madrid, Spain.
  • Viale G; 37Pathology Department, CIBERONC-Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain.
  • Hewitt SM; 38GEICAM-Spanish Breast Cancer Research Group, Madrid, Spain.
  • Bartlett JMS; 39Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN USA.
  • Penault-Llorca F; Roche Tissue Diagnostics, Digital Pathology, Santa Clara, CA USA.
  • Goel S; 41Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX USA.
NPJ Breast Cancer ; 6: 16, 2020.
Article in En | MEDLINE | ID: mdl-32411818
ABSTRACT
Assessment of tumor-infiltrating lymphocytes (TILs) is increasingly recognized as an integral part of the prognostic workflow in triple-negative (TNBC) and HER2-positive breast cancer, as well as many other solid tumors. This recognition has come about thanks to standardized visual reporting guidelines, which helped to reduce inter-reader variability. Now, there are ripe opportunities to employ computational methods that extract spatio-morphologic predictive features, enabling computer-aided diagnostics. We detail the benefits of computational TILs assessment, the readiness of TILs scoring for computational assessment, and outline considerations for overcoming key barriers to clinical translation in this arena. Specifically, we discuss 1. ensuring computational workflows closely capture visual guidelines and standards; 2. challenges and thoughts standards for assessment of algorithms including training, preanalytical, analytical, and clinical validation; 3. perspectives on how to realize the potential of machine learning models and to overcome the perceptual and practical limits of visual scoring.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: NPJ Breast Cancer Year: 2020 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: NPJ Breast Cancer Year: 2020 Document type: Article